Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangmeng Fu

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|July 29, 2025
Effect of a machine learning prediction model on the false-negative rate of sentinel lymph node biopsy for clinically node-positive breast cancer after neoadjuvant chemotherapyMinyan Chen, Tianzi Hong, Yali Wang, et al.
Biomedical Optics Express|November 8, 2021
Nomogram model combining macro and micro tumor-associated collagen signatures obtained from multiphoton images to predict the histologic grade in breast cancerGangqin Xi, Jiajia He, Deyong Kang, et al.
Breast Cancer Research and Treatment|September 13, 2020
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancerYuxiang Lin, Ling Lin, Fangmeng Fu, et al.
Frontiers in Immunology|June 10, 2026
Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinomaRenba Liang, Xinxiao Li, Manyi Zhu, et al.
Breast (Edinburgh, Scotland)|February 14, 2022
HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancerXiaobin Chen, Yuxiang Lin, Zhengwen Jiang, et al.
Journal of Cancer Research and Clinical Oncology|June 24, 2024
Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in ChinaJing Li, Peng He, Qindong Cai, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
Perineural invasion and risk of lymph node metastasis in early-stage operable breast cancer: a large-scale propensity-matched cohort study and meta-analysisWeifeng Cai, Yali Wang, Yibin Qiu, et al.
Surgery|March 25, 2026
Development and validation of an interpretable machine learning model integrating inflammatory blood biomarkers for predicting postoperative breast cancer-related lymphedema: A prospective cohort studyWeifeng Cai, Jingyan Feng, Lijuan He, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancerJiajia He, Fangmeng Fu, Wei Wang, et al.
NPJ Genomic Medicine|July 2, 2025
Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or youngerJing Li, Lili Chen, Xuhui Chen, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|July 29, 2025
Effect of a machine learning prediction model on the false-negative rate of sentinel lymph node biopsy for clinically node-positive breast cancer after neoadjuvant chemotherapyMinyan Chen, Tianzi Hong, Yali Wang, et al.
Biomedical Optics Express|November 8, 2021
Nomogram model combining macro and micro tumor-associated collagen signatures obtained from multiphoton images to predict the histologic grade in breast cancerGangqin Xi, Jiajia He, Deyong Kang, et al.
Breast Cancer Research and Treatment|September 13, 2020
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancerYuxiang Lin, Ling Lin, Fangmeng Fu, et al.
Frontiers in Immunology|June 10, 2026
Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinomaRenba Liang, Xinxiao Li, Manyi Zhu, et al.
Breast (Edinburgh, Scotland)|February 14, 2022
HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancerXiaobin Chen, Yuxiang Lin, Zhengwen Jiang, et al.
Journal of Cancer Research and Clinical Oncology|June 24, 2024
Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in ChinaJing Li, Peng He, Qindong Cai, et al.
Therapeutic Advances in Medical Oncology|March 26, 2026
Perineural invasion and risk of lymph node metastasis in early-stage operable breast cancer: a large-scale propensity-matched cohort study and meta-analysisWeifeng Cai, Yali Wang, Yibin Qiu, et al.
Surgery|March 25, 2026
Development and validation of an interpretable machine learning model integrating inflammatory blood biomarkers for predicting postoperative breast cancer-related lymphedema: A prospective cohort studyWeifeng Cai, Jingyan Feng, Lijuan He, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancerJiajia He, Fangmeng Fu, Wei Wang, et al.
NPJ Genomic Medicine|July 2, 2025
Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or youngerJing Li, Lili Chen, Xuhui Chen, et al.
Pageof 9